CIRC (01763.HK) has successfully won the bid for the design and construction of a million-curis gamma irradiation station project at the Bangladesh Institute of Nuclear Agriculture.
On June 11th, Geelong announced that China National Nuclear Corporation (CNNC) successfully won the bid for the Million-Curie Gamma Irradiation Station project of Bangladesh Nuclear Agriculture Research Institute (BNARI). The company adheres to the "overall coordination" development strategy of CNNC, actively organizes internal coordination within CNNC, and prepares core solutions such as irradiation station core equipment, irradiation sources for irradiation, and calibration. In the end, the company successfully won the bid for this project by competing with competitors from multiple countries using the "CNNC plan." The company worked closely with various related companies of CNNC to achieve the bidding of this project.
12 Health Care Stocks Moving In Monday's Intraday Session
GainersSeres Therapeutics (NASDAQ:MCRB) stock moved upwards by 34.0% to $0.82 during Monday's regular session. The company's market cap stands at $124.5 million. Renovaro (NASDAQ:RENB) shares increase
JonesTrading Maintains Curis(CRIS.US) With Buy Rating, Maintains Target Price $18
JonesTrading analyst Soumit Roy maintains $Curis(CRIS.US)$ with a buy rating, and maintains the target price at $18.According to TipRanks data, the analyst has a success rate of 26.0% and a total aver
Curis Price Target Maintained With a $26.00/Share by Truist Securities
Curis Price Target Maintained With a $26.00/Share by Truist Securities
Curis Is Maintained at Buy by Truist Securities
Curis Is Maintained at Buy by Truist Securities
Express News | Cantor Fitzgerald Reiterates Overweight on Curis
Express News | Curis Inc : Jonestrading Cuts Target Price to $18 From $27
Analysts Have Conflicting Sentiments on These Healthcare Companies: Curis (CRIS), Health Catalyst (HCAT) and Innate Pharma SA (OtherIPHYF)
Curis Inc Showcases Leukemia Study Breakthroughs at Conferences
Express News | Curis Inc: Data Update Expands Aml Dataset From 5 to 30 Patients
Express News | Curis Announces Additional Data From Takeaim Leukemia Study
China Nuclear Power (601985.SH): Currently, it is planned to produce no less than 150 Curi of carbon-14 per year
Gelonghui, May 14 | China Nuclear Power (601985.SH) said on the investor interactive platform that it currently plans to produce no less than 150 curi of carbon-14 per year, which can meet domestic carbon-14 demand, solve the problem of China's long-term carbon-14 dependency on imports, and at the same time create certain economic benefits for China's nuclear power.
Truist Financial Releases a Buy Rating on Curis (CRIS)
Curis to Present Updated Data From the TakeAim Leukemia Study
LEXINGTON, Mass., May 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibi
Curis, Inc. (NASDAQ:CRIS) Q1 2024 Earnings Call Transcript
Curis Price Target Maintained With a $26.00/Share by HC Wainwright & Co.
Curis Price Target Maintained With a $26.00/Share by HC Wainwright & Co.
Express News | HC Wainwright & Co. Reiterates Buy on Curis, Maintains $26 Price Target
Curis Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 53.54% HC Wainwright & Co. → $26 Reiterates Buy → Buy 02/09/2024 53.54% HC Wainwright & Co. $51
Curis Buy Rating Affirmed on Strong Earnings and Promising Emavusertib Trials
Curis Inc. Insiders Hold Steady: No New Trades Signal Confidence or Complacency?
No Data